China Traditional Chinese Medicine Holdings Past Earnings Performance
Past criteria checks 2/6
China Traditional Chinese Medicine Holdings's earnings have been declining at an average annual rate of -10.8%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been growing at an average rate of 5.4% per year. China Traditional Chinese Medicine Holdings's return on equity is 4.1%, and it has net margins of 5.3%.
Key information
-10.8%
Earnings growth rate
-10.8%
EPS growth rate
Pharmaceuticals Industry Growth | 6.0% |
Revenue growth rate | 5.4% |
Return on equity | 4.1% |
Net Margin | 5.3% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How China Traditional Chinese Medicine Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 17,204 | 917 | 7,180 | 640 |
31 Mar 24 | 17,663 | 1,101 | 7,318 | 663 |
31 Dec 23 | 18,122 | 1,285 | 7,457 | 686 |
30 Sep 23 | 17,909 | 1,107 | 7,280 | 647 |
30 Jun 23 | 17,696 | 930 | 7,102 | 608 |
31 Mar 23 | 16,000 | 847 | 6,331 | 610 |
31 Dec 22 | 14,304 | 764 | 5,559 | 612 |
30 Sep 22 | 15,560 | 1,091 | 6,411 | 665 |
30 Jun 22 | 16,815 | 1,417 | 7,262 | 717 |
31 Mar 22 | 17,934 | 1,675 | 7,917 | 706 |
31 Dec 21 | 19,053 | 1,933 | 8,572 | 694 |
30 Sep 21 | 17,677 | 1,897 | 7,781 | 647 |
30 Jun 21 | 16,300 | 1,861 | 6,990 | 600 |
31 Mar 21 | 15,553 | 1,762 | 6,662 | 575 |
31 Dec 20 | 14,806 | 1,663 | 6,334 | 550 |
30 Sep 20 | 14,423 | 1,562 | 6,074 | 525 |
30 Jun 20 | 14,039 | 1,461 | 5,814 | 500 |
31 Mar 20 | 14,180 | 1,525 | 5,813 | 482 |
31 Dec 19 | 14,321 | 1,588 | 5,813 | 464 |
30 Sep 19 | 13,528 | 1,563 | 5,391 | 435 |
30 Jun 19 | 12,735 | 1,538 | 4,970 | 406 |
31 Mar 19 | 11,997 | 1,488 | 4,424 | 376 |
31 Dec 18 | 11,259 | 1,439 | 3,877 | 347 |
30 Sep 18 | 10,579 | 1,386 | 3,586 | 288 |
30 Jun 18 | 9,900 | 1,332 | 3,295 | 230 |
31 Mar 18 | 9,119 | 1,251 | 3,032 | 216 |
31 Dec 17 | 8,338 | 1,170 | 2,768 | 202 |
30 Sep 17 | 7,785 | 1,123 | 2,595 | 205 |
30 Jun 17 | 7,233 | 1,075 | 2,422 | 208 |
31 Mar 17 | 6,883 | 1,021 | 2,360 | 198 |
31 Dec 16 | 6,533 | 967 | 2,298 | 187 |
30 Sep 16 | 6,010 | 880 | 2,147 | 184 |
30 Jun 16 | 5,487 | 794 | 1,995 | 181 |
31 Mar 16 | 4,598 | 670 | 1,732 | 147 |
31 Dec 15 | 3,709 | 546 | 1,468 | 112 |
30 Sep 15 | 3,271 | 509 | 1,309 | 72 |
30 Jun 15 | 2,833 | 471 | 1,151 | 32 |
31 Mar 15 | 2,742 | 444 | 1,138 | 16 |
31 Dec 14 | 2,650 | 417 | 1,125 | 0 |
30 Sep 14 | 2,384 | 370 | 999 | 0 |
30 Jun 14 | 2,117 | 324 | 872 | 0 |
31 Mar 14 | 1,756 | 261 | 725 | 0 |
31 Dec 13 | 1,395 | 198 | 577 | 0 |
Quality Earnings: CHIZ.F has high quality earnings.
Growing Profit Margin: CHIZ.F's current net profit margins (5.3%) are higher than last year (5.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CHIZ.F's earnings have declined by 10.8% per year over the past 5 years.
Accelerating Growth: CHIZ.F's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: CHIZ.F had negative earnings growth (-1.3%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (54.6%).
Return on Equity
High ROE: CHIZ.F's Return on Equity (4.1%) is considered low.